Evidence map›Paper›PMID 27941767›Full record

ArticleBone marrow transplantation2017

MDS disease characteristics, not donor source, predict hematopoietic stem cell transplant outcomes.

H Pourhassan, T DeFor, B Trottier, M Dolan, C Brunstein, N Bejanyan, C Ustun, E D Warlick

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bone marrow transplantation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Donor-Derived Cytokine-Induced Killer Cell Infusion as Consolidation after Nonmyeloablative Allogeneic Transplantation for Myeloid Neoplasms.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2019
    Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

H PourhassanBlood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN, USA.
T DeForBlood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN, USA.
B TrottierBlood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN, USA.
M DolanDepartment of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA.
C BrunsteinBlood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN, USA.
N BejanyanBlood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN, USA.
C UstunBlood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN, USA.
E D WarlickBlood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN, USA.

Funding

Women's CancerP30CA077598 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Douglas Yee · 1998 to 2026
$100.4M
Trial Design and Biostatistical Support CoreP01CA065493 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Mark J Osborn · 1995 to 2026
$48.2M
University of Minnesota Clinical and Translational Science Institute (UMN CTSI)UL1TR000114 · NCATS · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R · 2012 to 2015
$35.0M
NCATS NIH HHS UL1 TR000114NCI NIH HHS P01 CA065493NCI NIH HHS P30 CA077598
6 · The paper itself

Abstract

Myelodysplastic syndrome (MDS) is a heterogeneous group of hematological malignancies with considerably variable prognoses and curable only with hematopoietic cell transplantation (HCT). Few studies comparing MDS HCT outcomes between sibling and umbilical cord blood (UCB) donors exist. Using the University of Minnesota Blood and Marrow Transplant (BMT) database, we retrospectively analyzed HCT outcomes among 89 MDS patients undergoing either sibling or double UCB HCT in 2000-2013. We observed similar survival, relapse and non-relapse mortality between sibling and UCB donor sources. Relapse was increased in those with monosomal karyotype (P=0.04) and with reduced intensity conditioning (P<0.01). In summary, our data highlight similar MDS HCT outcomes regardless of donor source and support the use of UCB as an alternative donor when a sibling is unavailable.

Indexed as

Tissue DonorsAdultAgedCord Blood Stem Cell TransplantationDatabases, FactualHematopoietic Stem Cell TransplantationHumansKaryotypeMiddle AgedMyelodysplastic SyndromesPrognosisRecurrenceRetrospective StudiesSiblingsTransplantation ConditioningTreatment Outcome

Identifiers

PMID27941767
PMCPMC5382091

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.